ASH 2023 | Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT

Catherine Diefenbach, MD, NYU Langone, New York, NY, discusses the results of the Phase I/II E4412 trial (NCT01896999), which randomized patients with relapsed/refractory (R/R) classic Hodgkin lymphoma (HL) into one of two groups. One group was treated with a doublet regimen of nivolumab and brentuximab vedotin, and the second with a triplet regimen in which ipilimumab was added to the aforementioned doublet. There was no significant difference between the groups in the complete response (CR) rate or in the rate of toxicities of grade 3 or greater. Patients in both arms who proceeded to autologous stem cell transplantation (autoSCT) had improved progression-free survival (PFS) to that which is typically seen in patients treated with chemotherapy prior to autoSCT. Dr Diefenbach also comments on the differences in immune blood-based biomarkers between responders and non-responders in the Phase I portion of the trial. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.